JP4790959B2 - ヒトモノクローナル抗体を産生するための方法および組成物 - Google Patents

ヒトモノクローナル抗体を産生するための方法および組成物 Download PDF

Info

Publication number
JP4790959B2
JP4790959B2 JP2001561063A JP2001561063A JP4790959B2 JP 4790959 B2 JP4790959 B2 JP 4790959B2 JP 2001561063 A JP2001561063 A JP 2001561063A JP 2001561063 A JP2001561063 A JP 2001561063A JP 4790959 B2 JP4790959 B2 JP 4790959B2
Authority
JP
Japan
Prior art keywords
cell
human
cells
antigen
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001561063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531578A5 (cg-RX-API-DMAC10.html
JP2003531578A (ja
Inventor
ロンハオ リ，
Original Assignee
レイベン バイオテクノロジーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイベン バイオテクノロジーズ，インコーポレイティド filed Critical レイベン バイオテクノロジーズ，インコーポレイティド
Publication of JP2003531578A publication Critical patent/JP2003531578A/ja
Publication of JP2003531578A5 publication Critical patent/JP2003531578A5/ja
Application granted granted Critical
Publication of JP4790959B2 publication Critical patent/JP4790959B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001561063A 2000-01-26 2001-01-26 ヒトモノクローナル抗体を産生するための方法および組成物 Expired - Fee Related JP4790959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/491,894 2000-01-26
US09/491,894 US6541225B1 (en) 2000-01-26 2000-01-26 Methods and compositions for generating human monoclonal antibodies
PCT/US2001/002588 WO2001055216A1 (en) 2000-01-26 2001-01-26 Methods and compositions for generating human monoclonal antibodies

Publications (3)

Publication Number Publication Date
JP2003531578A JP2003531578A (ja) 2003-10-28
JP2003531578A5 JP2003531578A5 (cg-RX-API-DMAC10.html) 2011-06-30
JP4790959B2 true JP4790959B2 (ja) 2011-10-12

Family

ID=23954109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001561063A Expired - Fee Related JP4790959B2 (ja) 2000-01-26 2001-01-26 ヒトモノクローナル抗体を産生するための方法および組成物

Country Status (10)

Country Link
US (3) US6541225B1 (cg-RX-API-DMAC10.html)
EP (1) EP1255780B1 (cg-RX-API-DMAC10.html)
JP (1) JP4790959B2 (cg-RX-API-DMAC10.html)
KR (1) KR20020073185A (cg-RX-API-DMAC10.html)
CN (1) CN100491397C (cg-RX-API-DMAC10.html)
AT (1) ATE439380T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001231172B2 (cg-RX-API-DMAC10.html)
CA (1) CA2398284A1 (cg-RX-API-DMAC10.html)
DE (1) DE60139542D1 (cg-RX-API-DMAC10.html)
WO (1) WO2001055216A1 (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6794141B2 (en) * 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
JP2007514752A (ja) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
KR101295139B1 (ko) * 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
CA2597171A1 (en) * 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Antibodies to oncostatin m receptor
BRPI0607450A2 (pt) * 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
EP2343363A1 (en) * 2005-07-01 2011-07-13 John Schrader Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining
JP2009521228A (ja) * 2005-12-21 2009-06-04 ヴァックスデザイン コーポレーション 単球の樹状細胞への分化を促進する多孔質膜デバイス
CA2634123C (en) * 2005-12-21 2015-11-24 Vaxdesign Corporation In vitro germinal centers
KR100850416B1 (ko) * 2006-06-21 2008-08-04 남상윤 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법
US7709257B2 (en) * 2006-06-27 2010-05-04 Vax Design Corp. Models for vaccine assessment
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20090104221A1 (en) * 2007-07-06 2009-04-23 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009054556A1 (en) * 2007-10-24 2009-04-30 Sang Yun Nam Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity
WO2009072660A1 (ja) * 2007-12-03 2009-06-11 Kabushiki Kaisya Advance 抗体作製方法
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
TWI477603B (zh) * 2011-01-28 2015-03-21 鴻海精密工業股份有限公司 培育基體之製備方法
EP3363813A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2724157B1 (en) * 2011-06-27 2017-03-08 Valneva Method for screening cells
CN102321720B (zh) * 2011-07-28 2014-09-03 万晓春 一种混合细胞培养生产纯人源单克隆抗体的方法
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
US9395367B1 (en) 2016-02-29 2016-07-19 Rarecyte, Inc. Method to identify antigen-specific B cells for antibody development
US9442113B1 (en) 2016-02-29 2016-09-13 Rarecyte, Inc. Method to identify antigen-specific immune cells for therapeutic development
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0576383A (ja) * 1990-11-26 1993-03-30 Akzo Nv 抗体製造方法
WO1997023613A2 (en) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Cell activation process and reagents therefor
JPH09510607A (ja) * 1994-02-18 1997-10-28 カイロン コーポレイション Ｂ７−１特異的リガンド、およびｔ細胞アネルギーの誘導のためのそれらの使用
JPH10179160A (ja) * 1996-12-06 1998-07-07 Akzo Nobel Nv モノクローナル抗体の調製方法、モノクローナル抗体、医薬組成物及び診断試薬
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643971A (en) * 1983-03-11 1987-02-17 Sloan-Kettering Institute Monoclonal antibodies to human bladder and ureter cancers and method
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0218158A3 (en) 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
JPH09503901A (ja) 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0576383A (ja) * 1990-11-26 1993-03-30 Akzo Nv 抗体製造方法
JPH09510607A (ja) * 1994-02-18 1997-10-28 カイロン コーポレイション Ｂ７−１特異的リガンド、およびｔ細胞アネルギーの誘導のためのそれらの使用
WO1997023613A2 (en) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Cell activation process and reagents therefor
JPH10179160A (ja) * 1996-12-06 1998-07-07 Akzo Nobel Nv モノクローナル抗体の調製方法、モノクローナル抗体、医薬組成物及び診断試薬
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Also Published As

Publication number Publication date
CN1420893A (zh) 2003-05-28
DE60139542D1 (de) 2009-09-24
CA2398284A1 (en) 2001-08-02
US20060252124A1 (en) 2006-11-09
US20030109006A1 (en) 2003-06-12
US6541225B1 (en) 2003-04-01
ATE439380T1 (de) 2009-08-15
JP2003531578A (ja) 2003-10-28
WO2001055216A1 (en) 2001-08-02
KR20020073185A (ko) 2002-09-19
HK1050695A1 (en) 2003-07-04
EP1255780A1 (en) 2002-11-13
AU3117201A (en) 2001-08-07
EP1255780B1 (en) 2009-08-12
US8137668B2 (en) 2012-03-20
CN100491397C (zh) 2009-05-27
AU2001231172B2 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
US8137668B2 (en) Methods and compositions for generating human monoclonal antibodies
AU2001231172A1 (en) Methods and compositions for generating human monoclonal antibodies
KR20210138574A (ko) Dll3 표적화 키메라 항원 수용체 및 결합제
KR100868235B1 (ko) 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포
KR20090114432A (ko) 수지상 세포 아시알로당단백질 수용체(ｄｃ-ａｓｇｐｒ)를 통해 항원-제시 세포를 유도하는 제제
JP7459046B2 (ja) Ｓｔｅａｐ１に対するキメラ受容体及びその使用方法
AU2022263573B2 (en) Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof
KR20090127886A (ko) 수지상 세포 렉틴 유사 산화된 ｌｄｌ 수용체-1(ｌｏｘ-1)을 통한 사람 항원제시세포의 활성화
CA2468878A1 (en) Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
WO2024235019A1 (zh) 靶向dll3的抗体及其应用
JP2021518104A (ja) 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
KR20230084155A (ko) 면역치료 조성물
CN117964767B (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用
JP3515072B2 (ja) 成長因子模倣物質、成長因子および阻害因子の同定に用いられる方法および組成物
CN119060184B (zh) 抗rage抗体及其应用
US20030022249A1 (en) Antigen-binding fragments that recognize a subset of dendritic cells and methods of use thereof
CN119285778A (zh) 抗rage抗体及其应用
WO2024217585A1 (zh) 靶向ror1的抗体及其应用
HK1050695B (en) Methods for generating human monoclonal antibodies
CN100369934C (zh) 抗人4-1bbl单克隆抗体制备及其应用
RU2822366C2 (ru) Химерные антигенные рецепторы и связывающие агенты, нацеленные на dll3
CN119371542B (zh) 抗rage抗体及其应用
CN108251364A (zh) TCRab和CD45RA阳性细胞耗尽的细胞组合物
WO2022162009A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
WO2025005938A1 (en) Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110621

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110721

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140729

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees